Crystal Structure of Carboxyltransferase from Staphylococcus aureus Bound to the Antibacterial Agent Moiramide B by Silvers, Molly A. et al.
Louisiana State University 
LSU Digital Commons 
Faculty Publications Department of Biological Sciences 
8-23-2016 
Crystal Structure of Carboxyltransferase from Staphylococcus 
aureus Bound to the Antibacterial Agent Moiramide B 
Molly A. Silvers 
Louisiana State University 
Svetlana Pakhomova 
Louisiana State University 
David B. Neau 
Cornell University 
William C. Silvers 
UT Southwestern Medical School 
Nicholas Anzalone 
Louisiana State University 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.lsu.edu/biosci_pubs 
Recommended Citation 
Silvers, M., Pakhomova, S., Neau, D., Silvers, W., Anzalone, N., Taylor, C., & Waldrop, G. (2016). Crystal 
Structure of Carboxyltransferase from Staphylococcus aureus Bound to the Antibacterial Agent 
Moiramide B. Biochemistry, 55 (33), 4666-4674. https://doi.org/10.1021/acs.biochem.6b00641 
This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital 
Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital 
Commons. For more information, please contact ir@lsu.edu. 
Authors 
Molly A. Silvers, Svetlana Pakhomova, David B. Neau, William C. Silvers, Nicholas Anzalone, Carol M. 
Taylor, and Grover L. Waldrop 
This article is available at LSU Digital Commons: https://digitalcommons.lsu.edu/biosci_pubs/2818 
Crystal Structure of Carboxyltransferase from Staphylococcus 
aureus Bound to the Antibacterial Agent Moiramide B
Molly A. Silvers†, Svetlana Pakhomova†, David B. Neau§,‖, William C. Silvers⊥, Nicholas 
Anzalone†, Carol M. Taylor‡, and Grover L. Waldrop*,†
†Division of Biochemistry and Molecular Biology, Louisiana State University, Baton Rouge, 
Louisiana 70803, United States
‡Department of Chemistry, Louisiana State University, Baton Rouge, Louisiana 70803, United 
States
§Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 
14853-1301, United States
‖Northeastern Collaborative Access Team, Argonne National Laboratory, Argonne, Illinois 60439, 
United States
⊥Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas 
75390, United States
Abstract
The dramatic increase in the prevalence of antibiotic-resistant bacteria has necessitated a search 
for new antibacterial agents against novel targets. Moiramide B is a natural product, broad-
spectrum antibiotic that inhibits the carboxyltransferase component of acetyl-CoA carboxylase, 
which catalyzes the first committed step in fatty acid synthesis. Herein, we report the 2.6 Å 
resolution crystal structure of moiramide B bound to carboxyltransferase. An unanticipated but 
significant finding was that moiramide B bound as the enol/enolate. Crystallographic studies 
demonstrate that the (4S)-methyl succinimide moiety interacts with the oxyanion holes of the 
enzyme, supporting the notion that an anionic enolate is the active form of the antibacterial agent. 
Structure–activity studies demonstrate that the unsaturated fatty acid tail of moiramide B is needed 
only for entry into the bacterial cell. These results will allow the design of new antibacterial agents 
against the bacterial form of carboxyltransferase.
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As the frequency of antibiotic-resistant infections steadily increases, there is an urgent need 
for new antibacterial agents.1 Natural products or derivatives thereof constitute most of the 
antibiotics that are in current use clinically. Natural product antibiotics inhibit only four 
metabolic processes: DNA replication, transcription/translation, folate metabolism, and cell 
wall biosynthesis.2 A critical pathway in assembly of the bacterial cell wall is fatty acid 
synthesis. Thus, key enzymes in fatty acid biosynthesis can be considered targets for 
antibacterial development.3–5 There are only four natural product antibiotics that inhibit 
enzymes in fatty acid biosynthesis.1 One of those is moiramide B [compound 1 (Figure 
1A)], which inhibits acetyl-CoA carboxylase and is the subject of this report.
The first committed and regulated step in fatty acid synthesis is catalyzed by acetyl-CoA 
carboxylase (ACC).6 In most Gram-positive and Gram-negative bacteria, the enzyme 
consists of three discrete proteins: biotin carboxylase, biotin carboxyl carrier protein, and 
carboxyltransferase.7 These three proteins form a complex in vivo8 and catalyze the two-step 
reaction shown in Scheme 1. Biotin carboxylase (BC) catalyzes the first half-reaction in 
Scheme 1, which involves the ATP-dependent phosphorylation of bicarbonate to form a 
reactive carboxyphosphate intermediate.9 The carboxyl group is then transferred to the 
vitamin biotin, which in vivo, is covalently attached to the biotin carboxyl carrier protein 
(BCCP). The second half-reaction is catalyzed by the carboxyltransferase (CT) component, 
which transfers the carboxyl group from carboxybiotin to acetyl-CoA to make malonyl-
CoA. When BC and CT are purified, they retain their activity, processing free biotin rather 
than biotin attached to BCCP.10
Both the biotin carboxylase and the carboxyltransferase components of acetyl-CoA 
carboxylase have been validated as targets for antibacterial agents. Three different synthetic 
scaffolds have been reported to inhibit BC and exhibit antibacterial activity: 
pyridopyrimidines,11 aminooxazoles,12 and benzimidazole-carboxamides.13 In contrast, 
there is currently only one class of molecules known to inhibit CT, the natural products 
moiramide B and andrimid. Moiramide B [compound 1 (Figure 1A)] is a pseudopeptide that 
was extracted from a marine isolate of Pseudomonas fluorescens and was found to have 
broad-spectrum antibacterial activity.14 Ten years after the discovery of the antibiotic 
properties of moiramide B, Freiberg et al. determined that CT was the cellular target.15 
However, the mechanistic basis for moiramide B inhibition of CT was unclear.
Herein, we report the three-dimensional structure of moiramide B bound to 
carboxyltransferase. An interesting and important finding is that the enzyme binds the enol/
enolate of moiramide B (Figure 1B). Structure–activity studies of moiramide B are also 
described, which dissect moiramide B into fragments, and the functions of those fragments 
are determined with respect to the inhibition of CT and also the viability of Escherichia coli. 
Comparison of the results is instructive vis-à-vis the roles of the various functionalities in 
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moiramide B. The combined structure–function approach illustrates how nature has evolved 
a tight binding inhibitor (Ki = 5 nM) of CT with antibacterial activity,15 invoking many 
principles of medicinal chemistry. Our findings explain the molecular interactions between a 
lead compound, moiramide B, and the enzyme active site, laying the foundation for future 
design of antibacterial agents.
EXPERIMENTAL PROCEDURES
All chemicals and reagents were purchased from Sigma-Aldrich, Fisher, Acros, 
NovaBiochem, and Fluka and used without further purification. Diisopropylethylamine and 
triethylamine were dried and distilled from CaH2 and stored over KOH pellets. Dry 
methanol was distilled from Mg turnings and stored over 3 Å molecular sieves. All reactions 
were performed under a dry nitrogen atmosphere unless otherwise noted. Flash 
chromatography was performed using 230–400 mesh silica gel (40–63 μm) from Fluka. Thin 
layer chromatography was performed on aluminum-backed 60 F254 silica plates from EMD 
Chemicals, Inc. Optical rotations were recorded on a Jasco P-2000 digital polarimeter. 1H 
and 13C NMR spectra were recorded at room temperature on a Bruker AV-400 spectrometer. 
All NMR experiments were performed in deuterated solvents, and the chemical shifts are 
reported in standard δ notation as parts per million, using tetramethylsilane (TMS) and 
CDCl3 as internal standards with coupling constants (J) reported in hertz. High-resolution 
mass spectrometry (HRMS) was conducted using an Agilent 6210 electrospray ionization 
time-of-flight (ESI-TOF) mass spectrometer.
(3S)-Methyl-pyrrolidine-2,5-dione (2)
A catalytic amount of 5% Pd/C [100 mg, 20% (w/w)] was added to a solution of (4S)-
methyl-N-O-benzyl-pyrrolidine-2,5-dione16 (500 mg, 2.28 mmol, 1.00 equiv) in dry 
methanol (25 mL) and the mixture stirred under H2 for 1 h. The reaction mixture was 
filtered through a pad of Celite, washed with methanol, and concentrated. The residue was 
dissolved in acetonitrile (5 mL) and added dropwise to a stirred solution of 2-
bromoacetophenone (454 mg, 2.28 mmol, 1.00 equiv) in acetonitrile (5 mL) at room 
temperature. A solution of triethylamine (477 μL, 346 mg, 3.42 mmol, 1.50 equiv) in 
acetonitrile (2 mL) was added dropwise over 2 h, and the reaction mixture was stirred at 
room temperature overnight. The mixture was concentrated and then partitioned between 
CH2Cl2 (20 mL) and 5% hydrochloric acid (2 × 20 mL). The organic layer was washed with 
brine (20 mL), dried over MgSO4, filtered, concentrated, and purified by flash 
chromatography on silica gel eluting with a 5:1 CH2Cl2/EtOAc mixture to give 2 as a clear 
oil (25 mg, 10%): Rf = 0.56 (4:1 EtOAc:CH2Cl2); [α]D20−16.3 (c 0.13, MeOH); 1H NMR 
(CDCl3, 400 MHz) δ 1.37 (d, J = 7.2 Hz, 3H), 2.39 (dd, J = 16.1, 2.9 Hz, 1H), 2.81–3.07 (m, 
2H), 8.22 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 16.5, 36.2, 37.6, 176.4, 180.7; HRMS 
(ESI-TOF) calcd for C5H8NO2 (M + H)+ 114.0550, observed 114.0548.
(2E,4E)-N-[(S)-1-Phenylbutyl]hexa-2,4-dienamide (6)
Sorbic acid (50 mg, 0.45 mmol, 1.20 equiv) was added to a solution of (S)-1-
phenylbutylamine (55 mg, 0.37 mmol, 1.00 equiv) and TBTU (155 mg, 0.48 mmol, 1.30 
equiv) in DMF (5 mL) followed by addition of N,N-diisopropylethylamine (162 μL, 120 mg, 
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0.93 mmol, 2.50 equiv), and the mixture was stirred under N2 for 20 h. The solvent was 
removed in vacuo, and the resulting residue was purified by flash chromatography on silica 
gel eluting with a 1:1 Hex/EtOAc solvent to give 6 as a light yellow solid (66 mg, 73%): Rf 
= 0.56 (1:1 Hex:EtOAc); [α]D24−136.2 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 
0.90 (t, J = 7.3 Hz, 3H), 1.18–1.42 (m, 2H), 1.70–1.87 (m, 5H), 5.05 (q, J = 7.7 Hz, 1H), 
5.79 (d, J = 15.0 Hz, 1H), 5.95–6.23 (m, 3H), 7.10–7.38 (m, 6H); 13C NMR (CDCl3, 100 
MHz) δ 14.5, 17.9, 19.5, 38.4, 52.5, 122.5, 125.9, 127.5, 127.7, 129.3, 130.5, 136.8, 140.6, 
142.7, 165.7; HRMS (ESI-TOF) calcd for C16H22NO (M + H)+ 244.1696, observed 
244.1704.
Enzyme Purification
Carboxyltransferase from Staphylococcus aureus was purified as previously described.17 
Briefly, the genes encoding the α- and β-subunits of carboxyltransferase were placed in a 
minioperon such that the N-terminus of the α-subunit contained a His tag. The genes were 
overexpressed, and the protein was purified using nickel affinity chromatography followed 
by gel-filtration chromatography.
Crystallization and Data Collection
Crystals were obtained by sitting drop vapor diffusion at 22 °C using a solution of 16 
mg/mL carboxyltransferase and 0.5 mM moiramide B. The crystallization condition 
contained a reservoir solution of 0.1 M MES (pH 5.0) and 1.6 M NH4SO4. The sitting drop 
contained a well:protein volume ratio of 2:2 μL. Crystals appeared after 1–2 weeks and were 
cryoprotected with a 20% (v/v) ethylene glycol/reservoir solution, and then that solution was 
mixed with crystal mother liquor in a 1:1 ratio. The crystal was submerged in the 
cryoprotectant and then immediately flash-cooled in liquid nitrogen. X-ray diffraction data 
were collected to 2.6 Å at Advanced Photon Source beamline NE-CAT 24-ID-E equipped 
with the ADSC Q315r detector. The images were processed using the XDS program suite18 
and scaled using the Aimless program.19 Data collection and refinement statistics are listed 
in Table 1.
Crystal Structure Determination
The molecular replacement procedure was applied to locate a solution using MOLREP.20 A 
carboxyltransferase subunit of ACC from S. aureus (Protein Data Bank entry 2F9I) was used 
as a search model. The positioned MR model was refined using the maximum likelihood 
refinement in REFMAC20 with the TLS parameters generated by the TLSMD server.21 A 
difference Fourier map unambiguously revealed the presence of the inhibitor between the α- 
and β-chains (Figure 2a). The final model consists of residues 2–17 and 30–314 for the α-
chain, residues 29–241 and 247–283 for the β-chain, one Zn2+ cation, one inhibitor 
molecule, three sulfate anions, one ethylene glycol molecule, and 21 water molecules. 
Coot20 was used for model building throughout the refinement.
Kinetic Assays
Carboxyltransferase activity was measured in the reverse, nonphysiological direction and 
was determined spectrophotometrically by measuring the production of acetyl-CoA using 
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citrate synthase and malate dehydrogenase and following the reduction of NAD+ at 340 
nm.22 Each reaction mixture contained 0.12 mg/mL malate dehydrogenase, 0.05 mg/mL 
citrate synthase, 0.5 mM NAD+, 0.01 mM malic acid, 0.6 mg/mL bovine serum albumin 
(BSA), and 100 mM Tris (pH 8.0). All reactions had constant malonyl-CoA and biocytin (a 
biotin analogue) substrate concentrations of 150 μM and 6 mM, respectively. A final 
concentration of 50 nM of compounds 1 and 3–7 was added to measure the effect on 
activity. All reactions were conducted in a total of 0.5 mL in a 1 cm path length quartz 
cuvette, and all reactions were initiated by the addition of enzyme and measured in triplicate. 
Spectrophotometric data were collected using an Agilent Cary 60 UV–vis 
spectrophotometer interfaced with a personal computer with a data acquisition program 
supplied by Agilent.
Whole-Cell Growth Assays
A culture of E. coli strain JM109 was grown overnight in Luria-Bertani medium at 37 °C. 
Culture tubes containing 2 mL of fresh medium were inoculated with 10 μL of the saturated 
E. coli culture. Compounds 1 and 3–7 were dissolved in 100% DMSO to achieve a 5 mM 
stock solution and inoculated into tubes to generate final concentrations of 50 μM. After 
inoculation, the culture tubes were incubated for 4 h at 37 °C. Optical density (OD) readings 
were measured at 600 nm in 1 mL plastic cuvettes. Spectrophotometric data were collected 
using an Agilent Cary 60 UV–vis spectrophotometer.
RESULTS
Overall Structure of Moiramide B Bound to Carboxyltransferase
We previously described the synthesis of moiramide B on a milligram scale.16 
Carboxyltransferase from S. aureus (SaCT) was cocrystallized with the synthetic moiramide 
B. The structure of moiramide B bound to CT was determined and refined to a resolution of 
2.6 Å. Data collection statistics and refinement details are listed in Table 1. A difference 
Fourier map clearly established the presence of the moiramide B molecule in the active site 
of CT, which is located at the interface of the α- and β-subunits of the heterotetramer 
(Figure 2a).17 Binding in the active site is consistent with the observation that moiramide B 
exhibits competitive inhibition with respect to the substrates.15
Pohlmann et al. identified four characteristic fragments of moiramide B: (1) the 
pyrrolidinedione (succinimide) headgroup, (2) the L-valine-derived β-ketoamide, (3) β-
amino acid β-phenylalanine, and (4) the unsaturated fatty acid chain (Figure 1A).21 A key 
observation from the structure of moiramide B bound to SaCT is that the α-carbon between 
the ketone and amide is sp2-hybridized. It is not clear whether this is the enol tautomer of 
the β-ketoamide or the enolate anion [compound 2 (Figure 1B and Figure S1)]. During 
refinement, it became apparent that the fragment of moiramide B proximal to the sp2 carbon 
(particularly the L-valine side chain) would not fit the density with moiramide B in the keto 
form. In contrast, the enol/enolate of moiramide B readily fits the observed electron density. 
It is worth noting that for andrimid (the homologue of moiramide B with two additional 
carbons in the fatty acid chain), the pKa of the β-ketoamide has been determined to be 6.8 in 
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60% methanol in water.23 Thus, enolate formation and stabilization in the active site of the 
enzyme could be a facile process at physiological pH values.
The enolate of moiramide B is capable of hydrogen bonding interactions with CT that are 
stronger than those of the neutral β-ketoamide (Figure 2b,c). Most of the carbonyl and 
peptidic NH groups in moiramide B form one or more hydrogen bonds with residues from 
both the α- and β-subunits of CT. This contradicts an earlier report that andrimid, and by 
inference moiramide B, interacts solely with the β-subunit of CT.24 Each of the residues in 
CT that hydrogen bond with moiramide B is conserved between Gram-negative and Gram-
positive bacteria, which is consistent with the broad-spectrum antibacterial activity of 
moiramide B.14,15,25,26 Conserved residues in a protein suggest they are important for the 
function of the protein. The observation that moiramide B interacts with conserved residues 
also decreases the probability of a bacterium mutating one of these residues to become 
resistant to moiramide B. A detailed analysis of the structural features for each of the 
fragments of moiramide B (Figure 1A) follows.
Pyrrolidinedione Fragment
The crystal structure of moiramide B bound to carboxyltransferase reveals why the 
pyrrolidinedione is such a good isosteric and isoelectronic surrogate for the enolate of biotin. 
The partial double-bond character of the succinimidyl amides lends higher electron density 
to the oxygen (cf., a cyclopentadione), providing for a stronger interaction in the oxyanion 
hole. Sterically, the succinimide is a good fit, explaining why Pohlmann’s glutamide 
analogues had little activity (vide infra).21 In CT, oxyanion holes are needed to stabilize the 
enolates that form from each substrate during catalysis. In SaCT, the amide protons of 
adjacent glycine residues, Gly199 and Gly200 in the α-subunit [Gly199(α) and Gly200(α), 
respectively] and Gly207 and Gly208 in the β-subunit [Gly207(β) and Gly208(β), 
respectively], serve as hydrogen bond donors, constituting the oxyanion holes that stabilize 
the enolate and imidate anions in acetyl-CoA and biotin, respectively (Figure S2).17 It is 
interesting to note that the C2(=O) group in the pyrrolidinedione headgroup (fragment 1, 
numbering according to Needham et al.14) interacts directly with the amide hydrogen of 
Gly208(β) (Figure 2c). The C5(=O) group interacts with the hydroxyl group of Ser198, 
which is next to the oxyanion hole residue Gly199(α). On the basis of the orientation of 
moiramide B in the active site of CT, the keto groups of the pyrrolidinedione headgroup 
have allowed moiramide B to take advantage of the structural features of the enzyme, 
resulting in a potent inhibitor of CT that is also bactericidal.
The crystal structure of moiramide B bound to the CT complex helps to explain the results 
of previous structure–activity studies.26 Pohlmann et al. found that six-membered 
piperidinedione (glutamide) analogues of moiramide B did not exhibit any antibacterial 
activity. The imide carbonyls likely do not have the appropriate orientation to hydrogen bond 
with the active site amino acids. Moreover, Pohlmann et al. found that an increase in the 
bulk and hydrophobicity of substituents at the succinimide nitrogen resulted in a progressive 
decrease in both the IC50 and MIC values,26 indicating that the size of this moiety had an 
impact on enzyme inhibition and, thus, antibacterial activity.
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The crucial positioning of the pyrrolidinedione headgroup in the oxyanion holes is also 
corroborated by a mutation in carboxyltransferase that provides resistance to andrimid. 
Pantoea agglomerans, the bacterium that produces andrimid, is resistant to the antibacterial 
properties of its metabolite, because of a mutation in the β-subunit (M203L and T206L in E. 
coli and S. aureus carboxyltransferase, respectively).27 The Thr206 residue is adjacent to 
one of the residues in the β-subunit (Gly207 and Gly208) that form the oxyanion hole. 
Therefore, the T206L mutation could cause a local conformational change that weakens or 
eliminates the binding of andrimid (and by inference moiramide B) to the enzyme.
The structure–activity relationships in Pohlmann et al. indicated that the (4S)-methyl group 
on the pyrrolidinedione moiety was very important for antibacterial activity. Removal of the 
methyl group, inclusion of two methyl groups at position 4, or replacement with an ethyl 
group resulted in a total loss of activity.26,28 Thus, the methyl group contributes to the 
potency of moiramide B as an inhibitor of CT. However, the crystal structure does not 
provide an immediate explanation for this (e.g., nestling in a hydrophobic pocket of the 
appropriate size).
Because moiramide B was synthetic in origin, we had intermediates that could be readily 
accessed to probe the significance of the (4S)-methyl group, as well as the other structural 
characteristics of moiramide B. Compounds that are representative of the fragments of 
moiramide B (Figure 3) were tested for enzyme inhibition. Succinimide (3) is commercially 
available, and (3S)-methyl succinimide (4) was synthesized from an intermediate precursor 
during the synthesis of moiramide B (compound 1).16 Compounds 5 and 6 were also 
intermediates generated during the synthesis of moiramide B (compound 1).16 Compound 7, 
a stand-alone version of the “tail” fragment, was synthesized for this analysis.
The initial velocity of carboxyltransferase was measured in the presence of each of the 
compounds at 50 nM, while the concentrations of substrates malonyl-CoA and biocytin were 
held constant at a subsaturating level (Figure 4a and Table S1). Succinimide (compound 3) 
was, within error, not an inhibitor of carboxyltransferase. However, addition of the (4S)-
methyl substituent (compound 4) resulted in a 50% decrease in CT activity compared to that 
with the succinimide and an overall 65% decrease in activity when compared to the control. 
Thus, the methyl group contributes significantly to the inhibition of carboxyltransferase by 
moiramide B.
In the absence of structural evidence of the role of the methyl group, we propose three 
possible functions. First, the weakly electron-donating methyl group may contribute to the 
oxyanion character via an inductive effect, thereby strengthening the hydrogen bond 
interactions with the active site amino acids. Second, the reduced energy for desolvation of 
the methyl group (cf., a hydrogen) could increase binding affinity.29 Finally, the methyl 
group likely exerts an influence on the conformation of the pyrrolidinedione ring, already 
demonstrated to be key to effective binding. The observation that the methyl group in 
compound 4 leads to significant inhibitory activity relative to compound 3 is consistent with 
each of these hypotheses or some combination thereof (Figure 4a).
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There is a hydrophobic binding pocket for the side chain of the valine residue of moiramide 
B. The pocket is composed of Met170(β) and Val235(β), as well as Ile221(α) and 
Leu229(α) (Figure 5a). The binding pocket for the valine residue is not present in the 
unliganded structure of SaCT.17 The pocket could form as a result of moiramide B binding, 
or moiramide B binds to the conformation with the binding pocket that is in equilibrium 
with the unliganded conformation. Nonetheless, formation of the pocket closes off the 
binding site from the solvent (Figure 5b,c). An α-helix/loop motif in the β-subunit, which is 
composed of residues Ala231–Asn241 (α-helix) and Glu242–Asp247 (loop), undergoes a 
significant conformational change as a result of ligand binding (Figure 6). The loop segment 
becomes disordered with no observable electron density in the liganded structure. The 
largest movement (10.7 Å) is observed for the corresponding Cα atom of Asn241 of the 
native and liganded structures.
In addition to the movement of the α-helix/loop motif, a short stretch (Ser165–Arg169) of a 
β-sheet in the β-subunit moves slightly compared to the unliganded structure when 
moiramide B is bound to SaCT. This conformational change allows for the formation of 
hydrogen bonds between the carbonyl of Gly166 and both of the peptidic NH groups of 
valine and β-phenylalanine fragments, as well as a hydrogen bond between the peptidic NH 
group of Gly168 and the carbonyl oxygen of the L-valine β-ketoamide region (Figure 2c).
β-Phenylalanine Fragment
The comparison of CT inhibition by compounds 1 and 3–7 in Figure 4a indicates that while 
the attachment of the L-valine group (compound 5) increased the level of CT inhibition only 
slightly, the addition of the β-phenylalanine moiety (compound 6) increased the level of 
inhibition an additional 15%. This suggests that the β-phenylalanine moiety is an important 
component for increasing the binding affinity of moiramide B for the enzyme. As the 
number of hydrogen bonds increases with the addition of each “backbone amide” (i.e., the 
sequential addition of L-valine and β-phenylalanine residues), so does the binding affinity 
(Figure 2c).
There is no defined hydrophobic binding pocket for the phenyl ring of the β-phenylalanine 
residue. Indeed, there are no close interactions with any amino acids of the enzyme. Maybe, 
like the methyl group on the pyrrolidinedone ring, the phenyl side chain has a desolvation 
effect, leading to a higher affinity for carboxyltransferase. More importantly, this β-amino 
acid presents a favorable spatial relationship between the amide NH group and the C=O 
group to form hydrogen bonds with Gly166(β). Incorporation of an α-phenylalanine residue 
might afford the desolvation effect, but the NH group would be in the wrong location to 
engage in a productive hydrogen bond with Gly166(β). Moreover, we propose that in an α-
phenylalanine analogue, the phenyl group would provide steric interference for the oxyanion 
hole in the α-subunit (residues 206–208), as well as residues 231–233 of the β-subunit loop 
that moves in response to moiramide B binding.
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Unsaturated Fatty Acid Fragment
The unsaturated fatty acid tail interacts with Met134(β) and Leu229(β), and with 
Met179(α). These interactions are not particularly strong as indicated by the higher B 
factors for the atoms in the unsaturated fatty acid tail compared to the atoms of the other 
fragments of moiramide B. Moreover, Figure 4a shows that there is little difference in CT 
inhibitory activity between compounds 6 and 1, indicating little effect of the addition of the 
fatty acyl tail. Compound 7 itself, embodying the fatty acyl tail and a phenylamide 
functionality, exhibited no inhibition of CT, yet the bacterial cell expends considerable 
metabolic energy incorporating this moiety into moiramide B.24
The role of the unsaturated fatty acid becomes readily apparent if the antibacterial activities 
of compounds 1 and 3–7 are tested (Figure 4b). A final concentration of 50 μM for each 
compound was added to culture media inoculated with E. coli and incubated for 4 h. With 
the exception of moiramide B itself, none of the compounds exhibited any antibacterial 
activity (Figure 4b, Figure S3, and Table S2). Even though compounds 4–6 all inhibited CT 
significantly (Figure 4a), they did not display any antibacterial activity at a concentration of 
50 μM (Figure 4B). The only difference between compound 6 and moiramide B (compound 
1) is the incorporation of the fatty acyl tail. Therefore, it is tempting to suggest that the role 
of the fatty acyl tail in the mechanism of action of moiramide B is transport of the molecule 
into the bacterial cell.
DISCUSSION
Given the dominant role of natural products among clinically useful antibiotics, it is 
instructive to determine in detail how the only natural product inhibitor of acetyl-CoA 
carboxylase exerts its antibacterial effect. First, the observation that the bound form of the 
drug appears to be the enolate is important. The fact that the drug binds in its enolate form 
helps to explain the high affinity for the enzyme and by inference its potency as an 
antibacterial agent. The enolate form of moiramide B is stabilized in the oxyanion hole of 
carboxyltransferase, which is consistent with the fact that the enzyme must stabilize the 
enolates that form in both substrates, acetyl-CoA and biotin, during catalysis. While this 
finding has implications for understanding the catalytic mechanism of carboxyltransferase, 
on a more practical level, it also provides direction for the design of future inhibitors of 
carboxyltransferase. Second, the crystal structure reveals how nature expropriated the 
oxyanion holes in carboxyltransferase to utilize a molecule with the appropriate structural 
components to behave as a potent enzyme inhibitor. In nature’s version of structure-based 
drug design, a methyl pyrrolidinedione functionality evolved to inhibit carboxyltransferase 
by binding in the oxyanion holes found in both the α- and β-subunits. Third, in an example 
of nature mimicking a common technique in medicinal chemistry, the addition of a methyl 
group to the succinimide headgroup resulted in a significant increase in binding affinity. 
Thus, the evolution of moiramide B utilized two common approaches used in anthropogenic 
drug design. It will be interesting to see if these scaffolds can also be used in the design of 
inhibitors of human acetyl-CoA carboxylase II, which has a mechanism similar to that of the 
bacterial enzyme (i.e., it also utilizes two oxyanion holes for catalysis). The mitochondrial 
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isoform (or acetyl-CoA carboxylase II) is involved in regulating fatty acid oxidation and is a 
target for anti-obesity agents.30
While inhibition of the target enzyme is certainly important for an antibacterial agent, the 
ability to gain entry into the bacterium is equally important. The studies here show that the 
unsaturated fatty acid tail of moiramide B plays no role in inhibiting carboxyltransferase but 
is critical for the molecule to enter the bacterial cell. Thus, it is instructional to see how 
nature incorporated two distinct chemical moieties, a methyl pyrrolidinedione and an 
unsaturated fatty acid, into a single molecule to solve two distinct biological problems, 
enzyme inhibition and bacterial membrane transport. The lack of involvement of the 
unsaturated tail in binding to CT points to the possibility of modifying moiramide B for 
other applications. Conjugation of compound 6 with a fluorescent dye or moieties containing 
nuclides for positron emission tomography can lead to the development of molecular 
imaging agents for selectively detecting and imaging infectious diseases.31–33
The presence of the unsaturated fatty acid tail, along with the phenyl and valine side chains, 
makes moiramide B a very hydrophobic molecule. This is not characteristic of clinically 
useful molecules that have broad-spectrum antibacterial activity, which tend to be more 
polar.34 For example, broad-spectrum antibiotics typically have a logP (a measure of 
hydrophobicity) of less than zero (i.e., hydrophilic), whereas the logP for moiramide B is 
2.9. In fact, moiramide B has only one characteristic of broad-spectrum antibiotics, namely a 
molecular weight of <600 Da (457.6 Da). The results described in this report provide a 
blueprint from which to synthesize derivatives of moiramide B to increase solubility without 
affecting (or maybe even increasing) potency and chemical stability. Lastly, the lessons 
learned from analyzing how the natural process of evolution led to moiramide B will allow 
for the development of new antibacterial agents against a novel target molecule, acetyl-CoA 
carboxylase.
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ESI-TOF electrospray ionization time-of-flight
HRMS high-resolution mass spectrometry
NMR nuclear magnetic resonance
rmsd root-mean-square deviation
SaCT S. aureus carboxyltransferase
TMS tetramethylsilane
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Structure of moiramide B. (A) Moiramide B (compound 1) can be divided into four 
fragments: (1) pyrrolidinedione headgroup, (2) L-valine-derived β-ketoamide, (3) β-amino 
acid β-phenylalanine, and (4) unsaturated fatty acid chain. (B) Enolization between the C2 
carbonyl of the pyrrolidinedione headgroup and the carbonyl of L-valine β-ketoamide 
provides resonance around C3 of the pyrrolidinedione headgroup. The acidity of the α-
hydrogen of this diketone moiety allows for easy abstraction to generate an overall negative 
charge that is stabilized between these select carbonyls (compound 2).
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Moiramide B binds at the subunit interface of carboxyltransferase. (a) Moiramide B binds at 
the interface of the α-subunit (purple) and β-subunit (gold) of S. aureus carboxyltransferase, 
which is shown as a surface rendering. Moiramide B is represented as green sticks. (b) 
Stereoview of the moiramide B binding site of S. aureus carboxyltransferase. The Fo − Fc 
electron density map is contoured at 2.5σ. The map was calculated before inclusion of 
moiramide B atoms in the model. (c) Schematic diagram showing the interactions occurring 
between moiramide B and active site residues. Dashes and numbers indicate hydrogen bonds 
and distance in angstroms. Letters in parentheses indicate the subunit in which the residue is 
located, A for the α-subunit and B for the β-subunit.
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Structures of the moiramide B intermediates. Succinimide (3), (3S)-methyl-2,5-
pyrrolidinedione (4), (3S)-L-valine-(4S)-methyl-2,5-pyrrolidinedione (5), (3S)-β-
phenylalanine-L-valine-(4S)-methyl-2,5-pyrrolidinedione (6), moiramide B (1), and the fatty 
acyl tail fragment (7).
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Biological activity of the structural fragments of moiramide B. (a) Inhibitory activity of 
compounds 1 and 3–7. Initial velocities of carboxyltransferase were measured in the 
presence of each compound at 50 nM while the concentrations of the substrates, malonyl-
CoA and biocytin, were held at subsaturating levels (150 μM and 6 mM, respectively). 
Results were compared to the control (unless otherwise noted) using Student’s two-tailed t 
tests (±standard deviations). ns means not significant. *p < 0.05; **p < 0.01; ***p < 0.001. 
(b) Antibacterial activity of compounds 1 and 3–7. E. coli was inoculated with each 
compound at a final concentration of 50 μM and incubated at 37 °C. After a 4 h incubation, 
the absorbance at 600 nm was measured. Results were compared to the control using 
Student’s two-tailed t tests (±standard deviations). ****p < 0.0001.
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Hydrophobic binding interactions of moiramide B. (a) Hydrophobic binding pocket for the 
valine side chain of moiramide B (gray sticks). The residues that form the pocket include 
Met170(β) and Val235(β) (gold) and Ile221(α) and Leu229(α) (purple). Distances are in 
angstroms. (b) Binding cavity of moiramide B in S. aureus carboxyltransferase, which is 
represented as a surface rendering. The α-subunit is colored purple and the β-subunit gold. 
(c) Moiramide B ligand from the structure described in this report superimposed on 
unliganded S. aureus carboxyltransferase (Protein Data Bank entry 2F9I). The color coding 
is the same as in panel B.
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Movement of the α-helix/loop motif in the β-subunit of carboxyltransferase after the binding 
of moiramide B. The α-helix/loop motif in the unliganded enzyme is colored purple, while 
the liganded form is colored yellow. Moiramide B is represented in ball and stick format, 
and the protein is shown in surface representation with two residues from the β-subunit 
noted (Phe230 and Gln249).
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Reactions of Biotin Carboxylase (BC) and Carboxyltransferase (CT) Along with the Sum of 
the Entire Acetyl-CoA Carboxylase Reaction
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Table 1







 a (Å) 153.807
 b (Å) 49.445
 c (Å) 100.048
 β (deg) 91.94
no. of complexes per asymmetric unit 1
no. of unique reflections 23238
Rpima,b (%) 6.1 (46.0)
Rsymc (%) 9.1 (68.7)





resolution range (Å) 40–2.6
no. of reflections used in refinement 22099
σ cutoff used in refinement 0
R, Rfree(%)e 22.95, 27.59
no. of refined atoms
 protein 4264
 heterogeneous atoms 53
 water 21





 bonds (Å) 0.005
 angles (deg) 1.005
a
Values in parentheses are for the highest-resolution shell.
b
 , where ⟨Ihkl⟩ is the average of the symmetry (or 
Friedel)-related observations of a unique reflection, Ii is the intensity of the ith observation, and ⟨Ii⟩ is the mean intensity of the reflection.
c
Rsym = Σ|Ii−⟨Ii⟩|/ΣIi, where Ii is the intensity of the ith observation and ⟨Ii⟩ is the mean intensity of the reflection.
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d
Reported in ref 19.
e
R = Σ‖Fo| − |Fc‖/Σ|Fo|, where Fo and Fc are the observed and calculated structure factors amplitudes, respectively. Rfree is calculated using 4.8% 
of the reflections omitted from the refinement.
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